INTRODUCTION AND OBJECTIVES:
This study presents 2-year safety and efficacy data for prostatic artery embolization (PAE) to treat lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
METHODS: 84 patients undergoing PAE due to LUTS caused by BPH from April 2014 through August 2018 were retrospectively reviewed. 78 of these met inclusion criteria (age>44, LUTS without retention, failed medical therapy, International Prostate Symptom Score (IPSS)>12, Quality of Life score (QOL)>2). 6 were then excluded for bladder pathology. Subjects (n[72) had mean age 71.5AE9.1, mean Charlson comorbidity index (CCI) 3.4AE1.7, mean gland volume (PGV) 167AE107mL. After PAE, subjects were evaluated at 1, 3, 6, 12 and 24 months. Comparisons to baseline used T-tests (PGV, post void residual (PVR)) and Wilcoxon signed rank tests (IPSS, QOL). Associations between IPSS, QOL or PVR and age, CCI, PGV, or median lobe enlargement were analyzed by linear regression. Adverse events were recorded using Clavien-Dindo classification.
RESULTS: Mean improvements in IPSS and QOL at 1, 3, 6, 12 and 24 months after PAE are shown in Figure 1 (P<0.001 for all). Mean improvements in PVR and PGV at 3, 6, 12 and 24 months are shown in Figure 2 (P<0.001 for all, except P[NS at 24 months). Cohort sizes diminish due to ongoing cohort maturation, dementia preventing symptom quantification, and incomplete follow-up, with 4 (6%) technical failures. There was no association between age, CCI, PGV, or median lobe enlargement and IPSS, QOL or PVR at 3, 6 or 12 months after PAE (P[NS). 2 patients had grade 2 urinary infections (with 1 death due to immunocompromise); 1 patient had painful necrotic tissue resected at 8 months; 10 patients had grade 1 adverse events.
CONCLUSIONS: PAE safely and effectively produced sustained meaningful improvements in LUTS, PVR, and PGV at 2 years, independent of age, CCI, PGV, or median lobe enlargement. BPH patients excluded from transurethral procedures by these factors may undergo PAE and expect significant symptom improvement.
Source of Funding: None.
PD24-06 PROSTATIC ARTERY EMBOLIZATION TO TREAT GROSS HEMATURIA ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 3-YEAR OUTCOMES
Raj Ayyagari*, Taylor Powell, Julius Chapiro, Lawrence Staib, New Haven, CT; Shivank Bhatia, Miami, FL; Toby Chai, New Haven, CT; Steven Schoenberger, New London, CT; Ralph Devito, New Haven, CT INTRODUCTION AND OBJECTIVES: Prostatic artery embolization (PAE) is a minimally invasive angiographic procedure used to treat hematuria caused by benign prostatic hyperplasia (BPH). However scarce outcomes data exist on PAE for gross hematuria. This study presents medium-term safety and efficacy data for PAE to treat gross hematuria caused by BPH.
METHODS: 66 patients undergoing PAE in the setting of gross hematuria from December 2013 through August 2018 were reviewed retrospectively. Patients were included if cystoscopy found a large bleeding prostate and upper tract evaluation was negative. Patients were excluded for other hematuria sources (infection, stones or cancer) (n[11). 16 patients were treated for severe hematuria (SH) requiring continuous bladder irrigation (CBI) (age 79.8AE8.8, Charlson comorbidity index (CCI) 5.8AE2.5, prostate gland volume (PGV) 326AE171mL). 39 patients had gross hematuria (GH), but were embolized to treat urinary retention (17 patients: age 76.7AE9.0, CCI 4.1AE1.7, PGV 191AE79mL), or lower urinary tract symptoms (22 patients: age 74.0AE8.2, CCI 3.8AE1.6, PGV 232AE149mL). Follow-up occurred at 1, 3, 6, 12, 24, and 36 months. Adverse events were recorded using Clavien-Dindo classification.
RESULTS: 55 patients were included for study (no technical failures). 13/16 (81%) SH patients had CBI stopped 2-3 days after PAE and remained free of gross hematuria (mean follow-up[500AE501 days). 2 (13%) SH patients had recurrent hematuria requiring prostatic fulguration 52 and 60 days after PAE. 1 patient had recurrent hematuria 165 days later from new bladder tumor. 34/37 (92%) GH patients remained free of gross hematuria after PAE (mean follow-up[306-AE234 days). There were 2 deaths <30 days after PAE (1 from unrelated warfarin toxicity, 1 from urosepsis in an immunocompromised stage 4 cancer patient). There were 7 (13%) grade 2 urinary infections and 5 (9%) self-limited grade 1 adverse events. 26/29 (89%) patients with chronic catheters were successfully voiding within 2 months after PAE.
CONCLUSIONS: For patients with severe hematuria requiring CBI or gross hematuria caused by BPH, PAE is a safe, effective, and durable treatment. Embolization decreases glandular blood flow to stop bleeding, but also causes necrosis and shrinkage that relieves bladder outlet obstruction.
PD24-07 REAL WORLD OUTCOMES OF PROSTATIC URETHRAL LIFT CONFIRM CLINICAL STUDY RESULTS
Steven Gange*, Salt Lake City, UT; Ansar Khan, Fremont, NE; Gregg Eure, Virginia Beach, VA; Peter Walter, Cheektowaga, NY; Charles Chabert, Benowa, Australia; Paul Cozzi, Hurstville, Australia; Doug Grier, Edmonds, WA; Manish Patel, Elgin, SC; Sheldon Freedman, Las Vegas, NV; Peter Chin, Wollongong, Australia; Steven Ochs, Canton, OH; Andrew Hirsh, Somers, NJ; Michael Trotter, Austin, TX; Thomas Mueller, Voorhees, NJ INTRODUCTION AND OBJECTIVES: Recent clinical trials reveal significant advantages Prostatic Urethra Lift (PUL) provides patients suffering from LUTS/BPH, however few studies have evaluated outcomes in the real world. The objective of this study was to examine results of PUL within the largest unconstrained patient population. Analysis was also performed on site of service to assess procedural safety in an office setting.
METHODS: Retrospective chart review of 1,423 consecutive patients who received PUL across 14 sites in North America and Australia was performed. Symptom response (IPSS), quality of life (QoL) and peak flow rate (Qmax) were assessed at 1, 3, 6, 12 and 24 months post-procedure for the following cohorts: (1) total study population; (2) subjects with baseline IPSS ! 13. Patient follow up was analyzed using paired t-tests and 95% mean confidence intervals. IPSS outcomes from cohort 2 were compared to L.I.F.T. results at all timepoints. Incidence of post-procedural catheterization, surgical intervention and adverse events was analyzed and summarized descriptively.
RESULTS: Compared to L.I.F.T, subjects in the real-world registry were older (70 years, p<0.01), had lower baseline IPSS (19.2, p<.0001), QoL (4.0, p<.0001) and higher Qmax (12.6, p<.0001) scores. Following PUL, mean IPSS for cohort 1 improved significantly at all timepoints by at least 8.1 points (Table 1, p<.0001). QoL improved by an average of 42% and Qmax improvement ranged from 15-36% (Table 1) . Cohort 2 IPSS improvement was not significantly different compared to subjects from L.I.F.T. 61 surgical retreatments (excluding subjects with baseline urinary retention, prostate cancer and prostate size >80cc) occurred. Most adverse events were mild to moderate and transient. In the USA, 449 of 1146 (39%) procedures were performed in a clinic office, and 74.2% (333/ 449) were conducted using only local anesthesia. No significant differences in symptom outcomes and adverse events were observed between procedures conducted in the clinic office versus other settings.
CONCLUSIONS: The first ever analysis of patients who received PUL in a commercial setting demonstrates efficacy and implementation consistent with previous clinical studies. Site of service in the clinic office does not appear to change symptom response and safety.
Source of Funding: Neotract/Teleflex Inc.
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